- Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy2022 | Third Faculty of Medicine
- 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy2021 | Third Faculty of Medicine